Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington talked with Proactive's Stephen Gunnion about the company’s interim results and key clinical milestones. Skillington highlighted that Poolbeg ended June with £10 million in cash, supported by an upsized and oversubscribed £4.87 million fundraise earlier in the year. He said this extends the company’s cash runway into 2027, providing a strong foundation for advancing upcoming trials. One of the company’s main focuses is POLB 001, which is being developed to prevent cytokine release syndrome in patients undergoing cancer immunotherapies. “We expect to have interim data in the summer of 2026 that we can start sharing with our pharma colleagues,” Skillington noted. The trial will take place at the Christie NHS Foundation Trust under Dr Emma Searle, with support from Accelerating Clinical Trials (ACT). Skillington also discussed Poolbeg’s oral GLP-1 program, developed in partnership with AnaBio Technologies. This program uses an encapsulation technology to allow oral delivery of GLP-1, currently given mostly by injection. A rapid proof-of-concept trial is planned under Prof Carel le Roux at the University of Ulster, with data expected in the first half of 2026. Looking ahead, Skillington said Poolbeg is entering a “catalyst-rich period” with multiple updates expected that could attract pharmaceutical partners. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay informed. #PoolbegPharma #POLB001 #GLP1 #CancerImmunotherapy #Biotech #ClinicalTrials #Oncology #ObesityTreatment #DrugDevelopment #PharmaInnovation